申请人:The Upjohn Company
公开号:US03979444A1
公开(公告)日:1976-09-07
The invention relates to novel 4-hydroxymethyl(acyloxymethyl and methyl)-4-arylcyclohexylamines embraced by the formula ##SPC1## Wherein Ar is an aromatic ring selected from the group consisting of phenyl and naphthyl, each of which has from zero through three substituents independently selected from the group consisting of fluorine, chlorine, bromine, lower alkyl of one through three carbon atoms, lower alkoxy of one through three carbon atoms, and lower alkylthio of one through three carbon atoms; Z is selected from the group consisting of hydrogen, hydroxy and lower acyloxy of one through four carbon atoms; .about. is a generic expression denoting cis and trans stereoconfiguration and mixtures thereof, with the proviso that when the stereoconfiguration of the linkage connecting the cyclohexane ring and CH.sub.2 Z is cis to the amino group, the linkage connecting the cyclohexane and Ar rings is trans, and vice versa; R.sup.1 is selected from the group consisting of hydrogen and lower alkyl of one through three carbon atoms; R.sup.2 is selected from the group consisting of hydrogen, lower alkyl of one through three carbon atoms, ##EQU1## WHEREIN N IS 2 THROUGH 5 AND Ar has the same meaning as above; R.sup.1 and R.sup.2 taken together with --N< is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and substituted pyrrolidino, piperidino, hexamethylenimino, morpholino and piperazino; and pharmacologically acceptable acid addition salts thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (I) and novel derivatives thereof. The administration to humans and animals of the novel compounds (I) depresses their central nervous systems and lowers their blood pressures.
该发明涉及一种新型4-羟甲基(酰氧甲基和甲基)-4-芳基环己胺,其化学式如下:其中Ar是从苯基和萘基中选择的芳香环,每个环上独立选择的取代基包括氟、氯、溴、1至3个碳原子的低烷基、1至3个碳原子的低烷氧基和1至3个碳原子的低烷基硫基;Z选择自氢、羟基和1至4个碳原子的低酰氧基;~表示顺式和反式立体构型及其混合物,但当连接环己烷环和CH2Z的立体构型为顺时,连接环己烷环和Ar环的连接是反式,反之亦然;R1选择自氢和1至3个碳原子的低烷基;R2选择自氢、1至3个碳原子的低烷基、其中N为2至5且Ar的含义与上述相同;R1和R2与-N<一起构成从未取代和取代的吡咯啉基、哌啶基、六亚甲基基、吗啉基和哌嗪基中选择的饱和杂环氨基基团;以及其药理学上可接受的酸盐。它还涉及中间体和用于制备上述新化合物(I)及其新衍生物的过程。将该新型化合物(I)用于人类和动物,可抑制其中枢神经系统并降低其血压。